Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Abstract To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them....

Full description

Bibliographic Details
Main Authors: Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-89790-4

Internet

https://doi.org/10.1038/s41598-021-89790-4

Similar Items